Menzies-Gow Andrew, Flood-Page Patrick, Sehmi Roma, Burman John, Hamid Qutayba, Robinson Douglas S, Kay A Barry, Denburg Judah
Allergy and Clinical Immunology, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London.
J Allergy Clin Immunol. 2003 Apr;111(4):714-9. doi: 10.1067/mai.2003.1382.
Eosinophils develop from CD34(+) progenitors under the influence of IL-5. Atopic asthmatic individuals have increased numbers of mature eosinophils and eosinophil pro-genitors within their bone marrow and bronchial mucosa. We have previously reported that anti-IL-5 monoclonal antibody treatment decreases total bone marrow and bronchial mucosal eosinophil numbers in asthma.
Using an anti-IL-5 monoclonal antibody, we examined the role of IL-5 in eosinophil development within the bone marrow and bronchial mucosa in asthma.
Blood, bone marrow, and airway mucosal biopsy specimens were examined before and after anti-IL-5 (mepolizumab) treatment of asthmatic individuals in a double-blind, placebo-controlled trial. Numbers of mature and immature eosinophils were measured by histologic stain (bone marrow myelocytes, metamyelocytes, and mature eosinophils), flow cytometry (bone marrow and blood CD34(+)/IL-5Ralpha(+) cells), enumeration of bone marrow-derived eosinophil/basophil colony-forming units in methylcellulose culture, and sequential immunohistochemistry and in situ hybridization (bronchial mucosal CD34(+)/IL-5Ralpha mRNA(+) cells).
Mepolizumab decreased mature eosinophil numbers in the bone marrow by 70% (P =.017) in comparison with placebo and decreased numbers of eosinophil myelocytes and metamyelocytes by 37% (P =.006) and 44% (P =.003), respectively. However, mepolizumab had no effect on numbers of blood or bone marrow CD34(+), CD34(+)/IL-5Ralpha(+) cells, or eosinophil/basophil colony-forming units. There was a significant decrease in bronchial mucosal CD34(+)/IL-5Ralpha mRNA(+) cell numbers in the anti-IL-5 treated group (P =.04).
These data suggest that anti-IL-5 therapy might induce partial maturational arrest of the eosinophil lineage in the bone marrow. The reduction in airway CD34(+)/IL-5 mRNA(+) cell numbers suggests that IL-5 might also be required for local tissue eosinophilopoiesis.
嗜酸性粒细胞在白细胞介素-5(IL-5)的影响下由CD34(+)祖细胞发育而来。特应性哮喘患者骨髓和支气管黏膜内成熟嗜酸性粒细胞及嗜酸性粒细胞祖细胞数量增加。我们之前报道过,抗IL-5单克隆抗体治疗可减少哮喘患者骨髓和支气管黏膜中嗜酸性粒细胞的总数。
使用抗IL-5单克隆抗体,我们研究了IL-5在哮喘患者骨髓和支气管黏膜嗜酸性粒细胞发育中的作用。
在一项双盲、安慰剂对照试验中,对哮喘患者进行抗IL-5(美泊利单抗)治疗前后,检查其血液、骨髓和气道黏膜活检标本。通过组织学染色(骨髓中的髓细胞、晚幼粒细胞和成熟嗜酸性粒细胞)、流式细胞术(骨髓和血液中的CD34(+)/IL-5Ralpha(+)细胞)、甲基纤维素培养中骨髓来源的嗜酸性粒细胞/嗜碱性粒细胞集落形成单位计数,以及连续免疫组织化学和原位杂交(支气管黏膜中的CD34(+)/IL-5Ralpha mRNA(+)细胞)来测量成熟和未成熟嗜酸性粒细胞的数量。
与安慰剂相比,美泊利单抗使骨髓中成熟嗜酸性粒细胞数量减少70%(P = 0.017),使嗜酸性粒细胞髓细胞和晚幼粒细胞数量分别减少37%(P = 0.006)和44%(P = 0.003)。然而,美泊利单抗对血液或骨髓中CD34(+)、CD34(+)/IL-5Ralpha(+)细胞数量或嗜酸性粒细胞/嗜碱性粒细胞集落形成单位没有影响。抗IL-5治疗组支气管黏膜中CD34(+)/IL-5Ralpha mRNA(+)细胞数量显著减少(P = 0.04)。
这些数据表明,抗IL-5治疗可能诱导骨髓中嗜酸性粒细胞系的部分成熟停滞。气道中CD34(+)/IL-5 mRNA(+)细胞数量的减少表明,局部组织嗜酸性粒细胞生成可能也需要IL-5。